Ocular Therapeutix Sets Stage for Upcoming Investor Events
Ocular Therapeutix Gears Up for Key Conferences
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company dedicated to enhancing the retina experience, is making exciting moves with participation in notable investor and scientific conferences throughout September. Their commitment to innovation is evident as they prepare to share insights into their groundbreaking work in retinal therapies.
Investor Conferences on Horizon
Highlights from Morgan Stanley
On September 8, Ocular Therapeutix will be featured at the Morgan Stanley 23rd Annual Global Healthcare Conference. The highly anticipated fireside chat will occur from 2:35 PM to 3:10 PM ET, where Dr. Pravin U. Dugel, Executive Chairman, President, and CEO, will present and engage with investors.
Baird Conference Insights
Next, on September 9, the Baird 2025 Global Healthcare Conference will also include Ocular Therapeutix. Again, Dr. Dugel is set to share insights from 12:50 PM to 1:20 PM ET, allowing investors a closer look at the company’s future.
A live webcast of both fireside chats will be accessible on Ocular Therapeutix's website, ensuring that those unable to attend can still stay informed. Archived versions will be available for at least 30 days post-event.
Scientific Displays and Panels
Ocular Therapeutix will also partake in significant scientific events, starting with the EURETINA Innovation Spotlight on September 3. This event will be held in Paris, where critical presentations regarding ocular therapies will be showcased.
Your Invitation to EURETINA Events
On September 3, during the EURETINA Innovation Spotlight, Dr. Peter K. Kaiser, Chief Development Officer, will present on the topic: "Ocular Therapeutix: Redefining the Retina Experience." This presentation will commence at 4:00 PM CET, during the session focused on VEGF-related and other retinal indications.
Engagements at Ophthalmology Futures
Also, on September 3, Ocular Therapeutix will be active at the Ophthalmology Futures Forums (OFF) Retina Forum 2025 in Paris. This event will feature distinguished panels discussing pertinent issues like Diabetic Retinopathy and advances relating to Tyrosine Kinase Inhibitors. Various presentations will showcase expert insights on the future of ocular treatments, broadening understanding of these critical topics.
Additional Conference Participation
Following these events, Ocular Therapeutix will be engaged in the 25th EURETINA Congress from September 4-7. Here, they will delve into vital discussions surrounding retinal disease treatment and the promising potential of OTX-TKI to enhance treatment durability.
Moreover, the Retina Society's 58th Annual Scientific Meeting from September 10-13 will provide another platform for Ocular Therapeutix to illuminate their research and insights into retinal therapies.
Understanding the Company’s Vision
Ocular Therapeutix stands at the forefront of biopharmaceutical innovation. Their investigational product candidate, AXPAXLI™ (also referred to as OTX-TKI), is currently undergoing Phase 3 clinical trials for the treatment of wet age-related macular degeneration, demonstrating the company’s forward-focused research endeavors.
Pipeline of Promising Treatments
The company is not only advancing AXPAXLI but also leveraging their proprietary ELUTYX™ technology in various products, including DEXTENZA, an FDA-approved corticosteroid beneficial for ocular inflammation and pain management following surgery.
Frequently Asked Questions
What is Ocular Therapeutix known for?
Ocular Therapeutix is focused on innovative biopharmaceuticals, particularly in retinal therapies, with products like AXPAXLI for treating wet AMD.
When and where will the investor conferences take place?
Investor conferences will occur on September 8 and 9 in New York, with Dr. Pravin U. Dugel presenting key insights.
How can I watch the live presentations?
The live webcasts of the presentations can be watched on the Ocular Therapeutix website under the Events and Presentations section.
What are the major scientific forums Ocular is attending?
Ocular Therapeutix will participate in EURETINA and OFF Retina Forum 2025, addressing advancements in retinal disease treatments.
Who can I contact for more information?
For investor inquiries, you can reach out to Bill Slattery, Vice President of Investor Relations at Ocular Therapeutix.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
